We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Ixekizumab provides persistent improvements in health‐related quality of life and the sexual impact associated with moderate‐to‐severe genital psoriasis in adult patients during a 52‐week, randomised, placebo‐controlled, phase 3 clinical trial
- Authors
Ryan, C.; Guenther, L.; Foley, P.; Weisman, J.; Burge, R.T.; Gallo, G.; See, K.; McKean‐Matthews, M.; Bertram, C.C.; Merola, J.F.
- Abstract
Ixekizumab provides persistent improvements in health-related quality of life and the sexual impact associated with moderate-to-severe genital psoriasis in adult patients during a 52-week, randomised, placebo-controlled, phase 3 clinical trial 51% of patients in the PBO/IXE group achieved DLQI (0,1) at Week 52, and 94% of patients achieved DLQI item 9 (0,1) at Week 52 (Fig. In the group that received IXE in both periods (IXE/IXE), the proportion of patients with GPSIS-Avoidance (1,2) response persisted through Week 52, with 80% ( I n i = 24/30) achieving GPSIS-Avoidance (1,2).
- Subjects
CLINICAL trials; QUALITY of life; PATIENTS' attitudes; PSORIASIS; PSORIATIC arthritis; ADULTS
- Publication
Journal of the European Academy of Dermatology & Venereology, 2022, Vol 36, Issue 4, pe277
- ISSN
0926-9959
- Publication type
Article
- DOI
10.1111/jdv.17836